Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,486 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MR Clear all
Terminated Not applicable Interventional Results available

Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma.

NCT04376502
View directory record Official record
Conditions
Metastatic Carcinoma
Interventions
Radiation Therapy
Radiation
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 28, 2026, 3:55 AM EDT
Not listed Not applicable Interventional

MR-Guided Focused Ultrasound in the Treatment of Focal Epilepsy (EP001)

NCT02804230
View directory record Official record
Conditions
Epilepsy
Interventions
Neuro Ablation - Functional
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Stanford, California • Kansas City, Kansas • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 28, 2026, 3:55 AM EDT
Active, not recruiting Phase 2 Interventional

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

NCT04929028
View directory record Official record
Conditions
AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, HIV Infection, Rectal Squamous Cell Carcinoma, Stage II Rectal Cancer AJCC v8, Stage IIB Anal Cancer AJCC v8, Stage III Anal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Anoscopy, Biospecimen Collection, Capecitabine, Colonoscopy, Computed Tomography, Digital Rectal Examination, Echocardiography Test, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Lymph Node Biopsy, Magnetic Resonance Imaging, Mitomycin, Nivolumab, Positron Emission Tomography, Proctoscopy, Questionnaire Administration, Sigmoidoscopy
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
14
States / cities
San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Not applicable Interventional Results available

Mixed Reality Based System to Manage Phantom Pain Phantom Pain for Patients With Lower Limb Amputation

NCT04529083
View directory record Official record
Conditions
Phantom Limb Pain
Interventions
Mr. MAPP
Device
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 28, 2026, 3:55 AM EDT
Active, not recruiting Not applicable Interventional

Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer

NCT03289195
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI Biopsy
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Not yet recruiting Phase 2 Interventional

Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma

NCT07863765
View directory record Official record
Conditions
Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v8, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Unresectable Differentiated Thyroid Gland Carcinoma, Unresectable NUT Carcinoma, Unresectable Thyroid Gland Anaplastic Carcinoma, Unresectable Thyroid Gland Medullary Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Survey Administration, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Recruiting Not applicable Interventional

Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer

NCT07643012
View directory record Official record
Conditions
Endometrial Cancer
Interventions
MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT)
Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)

NCT01052428
View directory record Official record
Conditions
Mitral Regurgitation
Interventions
metoprolol succinate (Toprol XL), Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 28, 2026, 3:55 AM EDT
Recruiting Not applicable Interventional

CONFIRM: Magnetic Resonance Guided Radiation Therapy

NCT04368702
View directory record Official record
Conditions
Gastric Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Mantle Cell Lymphoma, Larynx Cancer, Bladder Cancer
Interventions
Viewray MRIdian® Linac
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Results available

MR Image Guided Therapy in Prostate Cancer

NCT01377753
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Visualase Thermal Therapy System
Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 28, 2026, 3:55 AM EDT
Completed No phase listed Observational

MR Imaging of Perinatal Brain Injury

NCT02008045
View directory record Official record
Conditions
Perinatal White Matter Brain Injury
Interventions
Magnetic Resonance Imaging, Neurodevelopmental Testing
Device · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
1 Day to 7 Years
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Recruiting Early Phase 1 Interventional

Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma

NCT07076472
View directory record Official record
Conditions
Progressive Glioblastoma, Recurrent Glioblastoma
Interventions
Aminolevulinic Acid Intravenous Formulation SONALA-001, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, MRI-Guided Focused Ultrasound Ablation, Oral Aminolevulinic Acid Hydrochloride
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Recruiting Early Phase 1 Interventional

Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)

NCT04861077
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
[18F]FMISO-PET with contrast-enhanced MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the MRI in Measuring the Cardiac Chambers and Thoracic Great Vessels

NCT00638664
View directory record Official record
Conditions
Cardiac Chambers
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics

NCT00645463
View directory record Official record
Conditions
Obesity
Interventions
CP-945,598
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2009 · Synced Oct 28, 2026, 3:55 AM EDT
Active, not recruiting No phase listed Observational

Rapid Pancreatic and Ovarian Screening MR Imaging With Motion Corrected T1, T2, and Advanced Diffusion Weighted Imaging for Patients With BRCA Mutation Who Undergo Screening Breast MRI

NCT02462460
View directory record Official record
Conditions
Screening Breast MRI in Patients Who Are BRCA Mutation Carriers
Interventions
MRI, Optional Screening Questionnaire
Device · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
30 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Recruiting Phase 1 Interventional

MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

NCT04808323
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Capecitabine, Initial Dose of Radiation before Dose Escalation, Cohort A: Dose Escalation Radiation, Cohort B: Dose Escalation Radiation, Cohort C: Dose Escalation Radiation, FOLFOX
Drug · Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Recruiting Phase 3 Interventional

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

NCT04166409
View directory record Official record
Conditions
Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma, WHO Grade 1 Glioma, WHO Grade 2 Glioma
Interventions
Biospecimen Collection, Carboplatin, Echocardiography Test, Magnetic Resonance Imaging, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 21 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
124
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Recruiting Phase 2 Interventional

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT05910801
View directory record Official record
Conditions
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lenalidomide, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Tafasitamab, Venetoclax
Procedure · Drug · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 28, 2026, 3:55 AM EDT
Recruiting Phase 1 Interventional

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

NCT05989828
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Aldesleukin, Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes, Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Mammogram, Multigated Acquisition Scan, Ultrasound Imaging
Biological · Procedure · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Early Phase 1 Interventional

68 Ga PSMA PET/MRI for Hepatocellular Carcinoma

NCT03982407
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
68Ga-PSMA-11 PET/MRI
Drug
Lead sponsor
Ajit H. Goenka, MD
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 28, 2026, 3:55 AM EDT
Completed No phase listed Observational

Infiltration of Gadolinium Injection in Brain MR Scans Using Artificial Intelligence

NCT05235646
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 28, 2026, 3:55 AM EDT
Recruiting Phase 2 Interventional

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

NCT06246357
View directory record Official record
Conditions
Hyperaldosteronism, Hypercortisolism, Cushing s Syndrome
Interventions
[68Ga]Ga-PentixaFor
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Recruiting No phase listed Observational

A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

NCT05705531
View directory record Official record
Conditions
Cardiovascular Disorder, Classic Hodgkin Lymphoma, Clonal Hematopoiesis
Interventions
Archive Sample Retrieval, Biospecimen Collection, Electronic Health Record Review, Magnetic Resonance Imaging, Survey Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
7 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
35
States / cities
Mobile, Alabama • Phoenix, Arizona • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 28, 2026, 3:55 AM EDT